Zydus Lifesciences Limited has informed the Exchange regarding a press release dated July 29, 2025, titled "Press Release on Update on Acquisition".
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zydus Lifesciences has completed the acquisition of an 85.6% stake in Amplitude Surgical, a French orthopaedic surgical technology company, at €6.25 per share for a total of €256 million. The deal was originally agreed on March 11, 2025, and all conditions have now been met. Zydus will file a simplified mandatory tender offer on July 30, 2025 for the remaining shares at the same price, and commitments from seven minority shareholders (4.7%) are expected to push its ownership above 90%, triggering a squeeze-out. The tender offer is expected to open in September 2025, subject to French market regulator AMF clearance. Amplitude Surgical, which generated nearly €111 million in revenue and employs 429 people, will retain its CEO Olivier Jallabert, who has also personally invested in the acquiring entity.
This move gives Zydus a controlling position in a leading European orthopaedic implant business, strengthening its global medical devices footprint and providing access to over 30 international markets. Shareholders should view this as a significant international expansion step, though the full financial impact will depend on successful completion of the tender offer and squeeze-out in the coming months.